Inflammation in Vein Graft Disease: A Genetic Approach

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Aortocoronary vein graft atherosclerosis afflicts over two million Americans. While it shares many features with atherosclerosis of native arteries, vein graft atherosclerosis progresses considerably more rapidly. Inasmuch as atherosclerosis is a chronic inflammatory disorder, inflammatory cytokines such as Tumor Necrosis Factor alpha (TNFalpha) might contribute to vascular lesion development. Preliminary studies demonstrate a strong proatherogenic activity of TNF on vascular smooth muscle cells (SMCs) in vitro. Our Central Hypothesis is that TNF contributes substantially to vein graft failure in vivo. While both activated macrophages and SMCs can produce TNF, the contribution of this cytokine to vein graft disease, and the cellular and molecular mechanisms by which TNF may accentuate vein graft atherosclerosis, are incompletely understood. To study these issues, we recently developed a new murine vein graft model that uses congenic inferior vena cavae to carotid artery interposition grafts. As a result, we can manipulate the genetic background of the vein graft wall independently from that of the recipient's circulating cells. Our preliminary studies show a significant reduction (40%) of vein graft neointima formation in grafts that are deficient in TNF receptor 1 signaling (TNFR1-/-), when placed into normolipidemic TNFR1-/- recipients. Our first aim is to determine the role of TNFalpha in vein graft atherosclerosis under normal and hyperlipidemic conditions in vivo. To achieve this aim, we will use wild type (C57Bl/6) or congenic apolipoprotein E deficient (ApoE-/-) mice as pro-atherogenic recipients of congenic vein grafts. The vein grafts will be derived from either wild type or TNF receptor-1-deficient (TNFR1-/-) mice. All of the recipient mice will also express the beta-galactosidase marker gene (from the Rosa 26 mouse strain) to allow for evaluation of vein graft infiltration by recipient-derived cells. Our second aim is to assess the potential for a recombinant TNF Inhibitor to attenuate vein graft neointima formation in mice with normal or elevated lipid levels. This will be achieved by examining vein graft remodeling in wild-type or ApoE-/- mice, that have been infected with a recombinant adenovirus expressing a p55TNFR1-IgG fusion protein that we have created. Defining cellular mechanisms by which TNF promotes vein graft atherosclerosis may have therapeutic implications for the many patients with vein graft disease.